Align Technology price target raised to $280 from $260 at UBS

UBS raised the firm’s price target on Align Technology to $280 from $260 and keeps a Neutral rating on the shares. Sentiment on Align’s Q4 results was mixed amid soft December orthodontia volumes data in the U.S., with poor weather and contributing to more acute concern around the Q1 outlook, but the better Q1 revenue outlook and full year guidance that matched subdued consensus revenues estimates and y/y margin improvement suggests better management visibility than over the past year, the analyst tells investors in a research note.